HuGE Literature Finder
Records
1
-
6
| ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics. Leukemia & lymphoma 2018 Feb 1-8. Kakosaiou Katerina, Panitsas Fotios, Daraki Aggeliki, Pagoni Maria, Apostolou Paraskevi, Ioannidou Agapi, Vlachadami Ioanna, Marinakis Theodoros, Giatra Chara, Vasilatou Diamantina, Sambani Constantina, Pappa Vassiliki, Manola Kalliopi |
| ASXL1 mutations are frequent in de novo AML with trisomy 8 and confer an unfavorable prognosis. Leukemia & lymphoma 2016 Oct 1-3. Zong Xiangping, Yao Hong, Wen Lijun, Ma Liang, Wang Qinrong, Yang Zhiluo, Zhang Tongtong, Chen Suning, Depei |
| Clinical significance of acquired somatic mutations in aplastic anaemia. International journal of hematology 2016 Mar . Marsh J C W, Mufti G |
| A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. PloS one 2016 11 (4): e0153016. Sloan Caroline E, Luskin Marlise R, Boccuti Anne M, Sehgal Alison R, Zhao Jianhua, Daber Robert D, Morrissette Jennifer J D, Luger Selina M, Bagg Adam, Gimotty Phyllis A, Carroll Mart |
| Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood cancer journal 2014 4 e177. Chen T-C, Hou H-A, Chou W-C, Tang J-L, Kuo Y-Y, Chen C-Y, Tseng M-H, Huang C-F, Lai Y-J, Chiang Y-C, Lee F-Y, Liu M-C, Liu C-W, Liu C-Y, Yao M, Huang S-Y, Ko B-S, Hsu S-C, Wu S-J, Tsay W, Chen Y-C, Tien H |
| ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013 Jan 27 (1): 82-91. Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann H-E, Kreuzer K-A, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jan 20, 2022
- Content source: